JP7260521B2 - タウタンパク質分解の化合物 - Google Patents

タウタンパク質分解の化合物 Download PDF

Info

Publication number
JP7260521B2
JP7260521B2 JP2020501505A JP2020501505A JP7260521B2 JP 7260521 B2 JP7260521 B2 JP 7260521B2 JP 2020501505 A JP2020501505 A JP 2020501505A JP 2020501505 A JP2020501505 A JP 2020501505A JP 7260521 B2 JP7260521 B2 JP 7260521B2
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
alkyl
formula
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020501505A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020527559A (ja
JP2020527559A5 (https=
Inventor
グレイ，ナタナエル，エス．
ジェイ． ハッガーティー，ステファン
ツァイ，クァン
リマ ダ シルヴィア，マリア カタリーナ テロバプティスタ
チャン，ティンフー
エム． フェルグソン，フルール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of JP2020527559A publication Critical patent/JP2020527559A/ja
Publication of JP2020527559A5 publication Critical patent/JP2020527559A5/ja
Priority to JP2023062212A priority Critical patent/JP2023106366A/ja
Application granted granted Critical
Publication of JP7260521B2 publication Critical patent/JP7260521B2/ja
Priority to JP2024209477A priority patent/JP2025060612A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/534—Production of labelled immunochemicals with radioactive label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
JP2020501505A 2017-07-12 2018-07-12 タウタンパク質分解の化合物 Active JP7260521B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023062212A JP2023106366A (ja) 2017-07-12 2023-04-06 タウタンパク質分解の化合物
JP2024209477A JP2025060612A (ja) 2017-07-12 2024-12-02 タウタンパク質分解の化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762531773P 2017-07-12 2017-07-12
US62/531,773 2017-07-12
PCT/US2018/041787 WO2019014429A1 (en) 2017-07-12 2018-07-12 COMPOUNDS FOR THE DEGRADATION OF TAU PROTEIN

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023062212A Division JP2023106366A (ja) 2017-07-12 2023-04-06 タウタンパク質分解の化合物

Publications (3)

Publication Number Publication Date
JP2020527559A JP2020527559A (ja) 2020-09-10
JP2020527559A5 JP2020527559A5 (https=) 2021-08-19
JP7260521B2 true JP7260521B2 (ja) 2023-04-18

Family

ID=65001509

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020501505A Active JP7260521B2 (ja) 2017-07-12 2018-07-12 タウタンパク質分解の化合物
JP2023062212A Withdrawn JP2023106366A (ja) 2017-07-12 2023-04-06 タウタンパク質分解の化合物
JP2024209477A Pending JP2025060612A (ja) 2017-07-12 2024-12-02 タウタンパク質分解の化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023062212A Withdrawn JP2023106366A (ja) 2017-07-12 2023-04-06 タウタンパク質分解の化合物
JP2024209477A Pending JP2025060612A (ja) 2017-07-12 2024-12-02 タウタンパク質分解の化合物

Country Status (7)

Country Link
US (2) US20210154184A1 (https=)
EP (2) EP3652329B1 (https=)
JP (3) JP7260521B2 (https=)
AU (1) AU2018300982B2 (https=)
CA (1) CA3069181A1 (https=)
ES (1) ES2965049T3 (https=)
WO (1) WO2019014429A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025060612A (ja) * 2017-07-12 2025-04-10 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド タウタンパク質分解の化合物

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2767532B1 (en) 2012-12-21 2016-07-13 National Institutes for Quantum and Radiological Science and Technology Novel compound for imaging tau protein accumulated in the brain
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
IL290809B2 (en) * 2016-11-01 2024-01-01 Arvinas Operations Inc Tau-protein targeting protacs and associated methods of use
BR112019017021A2 (pt) 2017-02-17 2020-04-14 Denali Therapeutics Inc anticorpos anti-tau e métodos de uso dos mesmos
LT3728207T (lt) 2017-12-21 2023-05-25 Ribon Therapeutics Inc. Chinazolinonai kaip parp14 inhibitoriai
EP3774804A1 (en) 2018-03-26 2021-02-17 Novartis AG N-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives
CA3095912A1 (en) * 2018-04-13 2019-10-17 Arvinas Operations, Inc. Cereblon ligands and bifunctional compounds comprising the same
CN118344338A (zh) 2018-04-23 2024-07-16 细胞基因公司 取代的4-氨基异吲哚啉-1,3-二酮化合物以及它们用于治疗淋巴瘤的用途
JP7293343B2 (ja) 2018-05-09 2023-06-19 アプリノイア セラピューティクス リミテッド ヘテロアリール化合物及びその使用
WO2020027225A1 (ja) 2018-07-31 2020-02-06 ファイメクス株式会社 複素環化合物
EP3841100A1 (en) 2018-08-20 2021-06-30 Arvinas Operations, Inc. Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases
JP7619952B2 (ja) * 2019-02-25 2025-01-22 シーエイチディーアイ ファウンデーション，インコーポレーテッド 変異型ハンチンチンタンパク質を標的とするための化合物及びその使用
CN120172958A (zh) 2019-04-12 2025-06-20 C4医药公司 Ikaros和aiolos的三环降解物
CN120398840A (zh) * 2019-06-19 2025-08-01 里邦医疗公司 用于治疗的parp14的靶向蛋白质降解
CN119954801A (zh) 2019-07-17 2025-05-09 阿尔维纳斯运营股份有限公司 Tau蛋白靶向化合物及相关使用方法
JP7785663B2 (ja) * 2019-09-16 2025-12-15 ノバルティス アーゲー 二機能性分解誘導薬及びそれらの使用方法
CA3161455A1 (en) * 2019-11-13 2021-05-20 Aprinoia Therapeutics Limited Compounds for degrading tau protein aggregates and uses thereof
CN110878095B (zh) * 2019-12-02 2023-01-24 中山大学 一种姜黄素双功能分子及其制备方法和应用
JP2023518202A (ja) * 2020-03-18 2023-04-28 ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド Ｐｅｔトレーサーｐｂｂ３に基づく異常タウの標的化ディグレーダー
EP4138921A1 (en) * 2020-04-23 2023-03-01 University Of Iowa Research Foundation Gper proteolytic targeting chimeras
CN116234562A (zh) * 2020-05-15 2023-06-06 非营利性组织佛兰芒综合大学生物技术研究所 用于治疗病理性聚集的手段和方法
EP4157833A1 (en) * 2020-05-28 2023-04-05 Bristol-Myers Squibb Company Galectin-3 inhibitors
JP2023530937A (ja) * 2020-06-17 2023-07-20 ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド Ｅ３－リガーゼ系の共動員を介した標的化された異常なα－シヌクレイン種ならびに誘導されたユビキチン化およびプロテアソームクリアランス
WO2022201063A1 (en) * 2021-03-23 2022-09-29 Covabind Joint Research Private Limited Nanoparticle composition for targeted protein degradation
JP2024517340A (ja) 2021-05-14 2024-04-19 アプリノイア セラピューティクス リミテッド アルファ－シヌクレイン凝集物を分解する化合物及びその使用
WO2022261627A1 (en) * 2021-06-07 2022-12-15 The General Hospital Corporation Inhibitors of ttbk1
CN115504963A (zh) * 2021-06-22 2022-12-23 苏州开拓药业股份有限公司 一种c-Myc蛋白降解剂
WO2023036936A1 (en) * 2021-09-09 2023-03-16 Booster Therapeutics Gmbh Bifunctional molecules as proteasome stimulators for improved targeted protein degradation, and their uses as targeted boosting degraders (tarbods)
EP4147723A1 (en) 2021-09-09 2023-03-15 Booster Therapeutics GmbH Bifunctional molecules as proteasome stimulators for improved targeted protein degradation, and their uses as targeted boosting degraders (tarbods)
EP4602166A2 (en) * 2022-10-11 2025-08-20 The General Hospital Corporation Engineered bifunctional receptors and uses thereof
WO2024182633A2 (en) * 2023-03-01 2024-09-06 The Regents Of The University Of California Targeted dephosphorylation of tau
CN116344058B (zh) * 2023-05-29 2023-08-18 之江实验室 一种基于图信号的阿尔兹海默风险标注方法及装置
WO2025117551A1 (en) * 2023-11-27 2025-06-05 Amydis, Inc. Amino acid derivatives for detecting neurological disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015060365A1 (ja) 2013-10-22 2015-04-30 クリノ株式会社 タウイメージングプローブ
WO2016105518A1 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
JP2016531851A (ja) 2013-09-26 2016-10-13 イーライ リリー アンド カンパニー タウ画像化剤の調製のための新規化合物および使用、ならびにタウ画像化製剤
WO2016197032A1 (en) 2015-06-04 2016-12-08 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8932557B2 (en) * 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
WO2013020125A1 (en) 2011-08-04 2013-02-07 Ats Holdings Llc Simplified spine testing device
JP6182668B2 (ja) * 2013-09-26 2017-08-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 画像化ツールとしてのイミダゾ［１，２−ａ］ピリジン−７−アミン
AU2015247817C1 (en) * 2014-04-14 2022-02-10 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
CA2988436A1 (en) * 2015-07-13 2017-01-19 Arvinas, Inc. Alanine-based modulators of proteolysis and associated methods of use
WO2017024318A1 (en) * 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
EP3337476A4 (en) * 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
IL290809B2 (en) * 2016-11-01 2024-01-01 Arvinas Operations Inc Tau-protein targeting protacs and associated methods of use
CN106543185B (zh) * 2016-11-10 2017-12-15 吉林大学 一种靶向泛素化降解plk1和brd4蛋白的化合物及其应用
EP3652329B1 (en) * 2017-07-12 2023-10-04 Dana-Farber Cancer Institute, Inc. Compounds for tau protein degradation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016531851A (ja) 2013-09-26 2016-10-13 イーライ リリー アンド カンパニー タウ画像化剤の調製のための新規化合物および使用、ならびにタウ画像化製剤
WO2015060365A1 (ja) 2013-10-22 2015-04-30 クリノ株式会社 タウイメージングプローブ
WO2016105518A1 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2016197032A1 (en) 2015-06-04 2016-12-08 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Cell Chem Biol，2016年04月，Vol.23, No.4，p.453-61

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025060612A (ja) * 2017-07-12 2025-04-10 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド タウタンパク質分解の化合物

Also Published As

Publication number Publication date
JP2020527559A (ja) 2020-09-10
EP3652329A1 (en) 2020-05-20
JP2023106366A (ja) 2023-08-01
CA3069181A1 (en) 2019-01-17
EP4310496A2 (en) 2024-01-24
ES2965049T3 (es) 2024-04-10
EP3652329A4 (en) 2021-06-30
WO2019014429A1 (en) 2019-01-17
US20210154184A1 (en) 2021-05-27
EP3652329B1 (en) 2023-10-04
EP4310496A3 (en) 2024-12-04
US20240091213A1 (en) 2024-03-21
AU2018300982B2 (en) 2025-01-09
AU2018300982A1 (en) 2020-01-16
JP2025060612A (ja) 2025-04-10

Similar Documents

Publication Publication Date Title
JP7260521B2 (ja) タウタンパク質分解の化合物
JP7097880B2 (ja) Ｍａｌｔ１分解のための化合物
JP7308146B2 (ja) インターロイキン１受容体関連キナーゼの阻害剤およびその使用
JP7472026B2 (ja) 選択的なタンパク質分解を誘導するための低分子およびその使用法
JP7258748B2 (ja) サイクリン依存性キナーゼ１２（ｃｄｋ１２）の阻害剤およびその使用
JP7785108B2 (ja) 血漿カリクレインの阻害剤およびその使用
JP7590185B2 (ja) Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
AU2018342105B2 (en) Use of metformin and analogs thereof to reduce ran protein levels in the treatment of neurological disorders
JP7142022B2 (ja) Ｍａｌｔ１の阻害剤およびそれらの使用
JP7675070B2 (ja) 治療、特にｍｙｄ８８変異疾患における使用のためのｈｃｋ阻害剤としてのピラゾロピリミジン誘導体
JP7185631B2 (ja) 抗線維化化合物
JP2025513813A (ja) ヒストン脱アセチル化酵素６（ｈｄａｃ６）の阻害
AU2019318046B2 (en) Histone demethylase 5 inhibitors and uses thereof
HK40106846A (en) Compounds for tau protein degradation
CA3218510A1 (en) Small molecule modulators of glucocerebrosidase activity and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210712

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210712

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220805

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230105

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230307

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230406

R150 Certificate of patent or registration of utility model

Ref document number: 7260521

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250